Article Information
History
- April 20, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Carolina Garrido, PhD1,*,
- Jillian H. Hurst, PhD2,3,*,
- Cynthia G. Lorang, MS1,
- Jhoanna N. Aquino, BS2,
- Javier Rodriguez4,
- Trevor S. Pfeiffer1,
- Tulika Singh1,
- Eleanor C. Semmes, BS1,3,5,
- Debra J. Lugo, MD2,
- Alexandre T. Rotta, MD6,
- Nicholas A. Turner, MD, MHSc7,
- Thomas W. Burke, PhD9,
- Micah T. McClain, MD7,8,9,
- Elizabeth A. Petzold, PhD4,
- Sallie R. Permar, MD, PhD8,
- M. Anthony Moody, MD1,2,
- Christopher W. Woods, MD, MPH1,7,8,9,
- Matthew. S. Kelly, MD, MPH2,* and
- Genevieve G. Fouda, MD, PhD1,2,*,†
- 1Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC
- 2Department of Pediatrics, Division of Infectious Diseases, Duke University School of Medicine, Durham, NC
- 3Children’s Health & Discovery Institute, Department of Pediatrics, Duke University School of Medicine, Durham, NC
- 4Children’s Clinical Research Unit, Department of Pediatrics, Duke University School of Medicine, Durham, North Carolina, USA
- 5Medical Scientist Training Program, Department of Molecular Genetics and Microbiology, Duke University, Durham, NC
- 6Department of Pediatrics, Division of Pediatric Critical Care Medicine, Duke University School of Medicine, Durham, NC
- 7Department of Medicine, Division of Infectious Diseases, Duke University School of Medicine, Durham, NC
- 8Durham Veterans Affairs Medical Center, Durham, NC
- 9Center for Applied Genomics and Precision Medicine, Duke University, Durham, NC
- 10Department of Pediatrics, Weill Cornell School of Medicine, New York City, NY
- ↵†Corresponding Author: Genevieve G. Fouda, MD, PhD, 2 Genome Court, Durham, NC 27710, Phone: 919-681-0608, Email: genevieve.fouda{at}duke.edu
↵* These authors contributed equally to the manuscript.
Posted April 20, 2021.
Asymptomatic or mild symptomatic SARS-CoV-2 infection elicits durable neutralizing antibody responses in children and adolescents
